Fig. 4From: The crystal structure of titanium dioxide nanoparticles influences immune activity in vitro and in vivoa. Percentage of lymphocytes in the BALF after OVA challenge. b. Number of lymphocytes in the BALF after OVA challenge. c. Percentage of lymphocytes in the balf after ova sensitization and challenge. d. Number of lymphocytes in the BALF after OVA sensitization and challenge. See legend to Fig. 3 . In A and B, (*) and (**) P < 0.05 and P < 0.01 vs. PBS alone; (+) P < 0.05 vs. rutile NP. In C and D, (*), (**) and (**) P < 0.05, P < 0.01 and P < 0.01 vs. OVA alone; (+) P < 0.05 vs. OVA + rutile NP; (##) P < 0.05 vs. OVA + anatase NPBack to article page